Last updated: September 8, 2026
Vimizim, BioMarin Pharmaceutical’s elosulfase alfa, is a high-value enzyme-replacement therapy for mucopolysaccharidosis type IV A, also known as Morquio A syndrome. The product has maintained annual revenue in the several-hundred-million-dollar range through a combination of orphan-disease exclusivity, limited competition, chronic weekly dosing, and a small but durable global patient population. Its primary commercial risks are reimbursement pressure, manufacturing complexity, treatment discontinuation, and future biosimilar competition rather than conventional generic substitution.
What is Vimizim and which patients does it treat?
Vimizim is an intravenously administered recombinant form of N-acetylgalactosamine-6-sulfatase, or GALNS. GALNS deficiency causes progressive accumulation of keratan sulfate and chondroitin-6-sulfate in patients with Morquio A syndrome.
| Attribute |
Vimizim detail |
| Active ingredient |
Elosulfase alfa |
| Sponsor |
BioMarin Pharmaceutical Inc. |
| FDA application |
BLA 125460 |
| FDA approval |
February 28, 2014 |
| Indication |
Mucopolysaccharidosis type IV A |
| Administration |
Intravenous infusion once weekly |
| Treatment setting |
Hospital, infusion center or specialized clinic |
| Regulatory category |
Biologic and orphan drug |
| Primary market |
United States, Europe and other specialty-care markets |
The FDA approved Vimizim under the orphan-drug framework based on clinical data showing increased urinary keratan sulfate clearance and improvement in a six-minute walk assessment in a subset of treated patients. The label also includes warnings for hypersensitivity and infusion-associated reactions. Premedication and monitoring are required in clinical practice.[1]
Vimizim is a disease-modifying treatment, but it does not reverse established skeletal abnormalities. The requirement for lifelong or extended-duration weekly infusions limits convenience and creates a recurring exposure to infusion-center capacity, patient adherence and payer authorization.
How large is the Vimizim market?
The addressable population is small. Morquio A is a rare autosomal-recessive disorder, and many patients are diagnosed during childhood or adolescence. The commercial market is therefore driven by treatment penetration and duration, not by broad population expansion.
BioMarin has not generally disclosed Vimizim patient counts in a way that permits a precise global market-share calculation. Public company disclosures indicate that Vimizim became a several-hundred-million-dollar product after its initial launch and has remained material to BioMarin’s specialty portfolio.
Vimizim revenue trajectory
The following trajectory summarizes BioMarin’s reported product-revenue pattern using rounded figures from annual filings and company disclosures.
| Period |
Approximate annual Vimizim revenue |
Commercial interpretation |
| 2014 |
Less than $50 million |
Partial-year U.S. launch |
| 2015-2017 |
Approximately $100 million to $300 million |
Rapid patient enrollment and international expansion |
| 2018-2020 |
Approximately $350 million to $450 million |
Mature orphan-drug commercialization |
| 2021-2024 |
Approximately $400 million to $500 million |
Stable mature-product revenue base |
Revenue growth was strongest during the first several years after U.S. approval. The later trajectory has been comparatively stable, reflecting the small eligible population and the absence of an FDA-approved direct competitor. BioMarin’s portfolio disclosures place Vimizim among its recurring rare-disease revenue generators alongside Naglazyme, Brineura, Palynziq and other specialty products.[2][3]
The product’s revenue is more resilient than that of a conventional primary-care medicine because treatment is medically necessary, diagnosis is highly specialized and switching options are limited. Its growth rate is constrained by the number of diagnosed patients, disease progression, treatment discontinuation and country-specific reimbursement decisions.
What is the annual cost of Vimizim treatment?
Vimizim has a high annual treatment cost that varies with patient weight, dosing, discounts, payer contracts and infusion-related charges. The labeled dose is 2 mg per kilogram administered weekly. A patient weighing 30 kilograms receives a materially lower annual drug quantity than a patient weighing 60 kilograms.
The commercial cost structure includes:
- Drug acquisition cost.
- Weekly infusion administration.
- Premedication and monitoring.
- Management of infusion-associated reactions.
- Laboratory and specialist follow-up.
- Travel and caregiver costs for pediatric patients.
Public list-price estimates have historically placed annual drug costs in the high-six-figure range for many patients, although net realized revenue is lower after rebates, discounts, government-program adjustments and international pricing controls. BioMarin’s financial statements report net product revenue rather than gross list-price sales.[2]
The weight-based dosing model creates a natural revenue expansion mechanism as pediatric patients grow. That effect is offset by discontinuation, mortality, payer restrictions and treatment decisions in patients with advanced skeletal disease.
When does Vimizim lose exclusivity?
Vimizim’s U.S. orphan-drug exclusivity began with the FDA approval on February 28, 2014. The seven-year orphan exclusivity period generally expired in February 2021.[1][4]
Orphan exclusivity is separate from patent protection and does not prevent all later competition. It prevents FDA approval of another product for the same orphan indication when the competing product is considered the same drug, unless statutory exceptions apply.
| Exclusivity right |
Approximate status |
| U.S. orphan-drug exclusivity |
Expired in February 2021 |
| U.S. biologic reference-product exclusivity |
Expired after the 12-year BPCIA period, generally in 2026 |
| Conventional small-molecule generic pathway |
Not applicable |
| Biosimilar pathway |
Potentially available after reference-product exclusivity and applicable patent barriers |
| Pediatric exclusivity |
No publicly material extension identified for Vimizim |
The 12-year U.S. reference-product exclusivity period for a biologic approved in 2014 generally runs into 2026. That date is important because a biosimilar applicant may have regulatory advantages before commercial launch, but the reference product’s statutory exclusivity and patent disputes still affect market entry timing.[5]
What patents protect Vimizim?
Vimizim is protected through a combination of biologic exclusivity, manufacturing know-how, process controls, formulation knowledge and patents that may cover the molecule, production methods, purification, glycosylation or therapeutic use.
Unlike a small-molecule medicine, Vimizim’s commercial protection cannot be evaluated from a single compound patent. A biosimilar applicant must demonstrate similarity across structural, functional, pharmacokinetic and immunogenicity attributes. Differences in glycosylation, aggregation, impurities and biological activity can create regulatory and manufacturing barriers.
The principal protection categories are:
| Protection category |
Relevance to Vimizim |
| Composition or protein claims |
May cover elosulfase alfa or defined molecular forms |
| Cell-line and expression claims |
May cover recombinant production systems |
| Manufacturing-process patents |
May cover fermentation, purification and quality-control steps |
| Formulation claims |
May cover stability, concentration and storage conditions |
| Method-of-use claims |
May cover treatment of Morquio A or enzyme-deficiency disorders |
| Trade secrets |
May cover cell banks, process parameters and release specifications |
The FDA’s Orange Book is not the controlling patent source for Vimizim because Vimizim is a biologic, not a conventional small-molecule drug. Biologic reference products are tracked through the FDA Purple Book and the patent-information procedures under the Biologics Price Competition and Innovation Act, or BPCIA.[5][6]
What is the Orange Book and Purple Book status of Vimizim?
Vimizim does not have the standard Orange Book listing structure used for products approved through an NDA. The relevant FDA framework is:
- BLA 125460 establishes the licensed biologic.
- The Purple Book identifies the reference product and its biosimilar status.
- Patent information is exchanged between the reference-product sponsor and a biosimilar applicant under the BPCIA patent dance.
- Patent litigation may follow under 35 U.S.C. § 271(e)(2), but it is not the same process as a typical Hatch-Waxman Paragraph IV case.
No FDA-approved biosimilar to Vimizim has been publicly identified in the available regulatory record through the latest cited period. No conventional ANDA-based generic launch is available because elosulfase alfa is a complex biologic.
Are there Paragraph IV challenges to Vimizim?
A traditional Paragraph IV challenge applies to an ANDA filed for a small-molecule drug. Vimizim is subject to the BPCIA biosimilar framework instead.
The practical equivalents of a Paragraph IV challenge are:
- A biosimilar application under section 351(k) of the Public Health Service Act.
- Exchange of patent information with BioMarin.
- Declaratory or infringement litigation involving process, formulation, composition or use patents.
- A commercial-launch decision after regulatory approval and patent negotiations.
No prominent public Vimizim biosimilar litigation or settlement agreement has been identified in the cited FDA and BioMarin materials. The lack of a public challenge reduces near-term entry visibility but does not eliminate longer-term biosimilar risk.
How strong is the Vimizim patent estate?
Vimizim’s practical exclusivity is stronger than its orphan exclusivity alone suggests, but its patent strength is difficult to reduce to a single expiration date.
The strongest barriers are likely to be:
- High-complexity recombinant production.
- Control of the commercial cell bank.
- Difficult-to-reproduce glycosylation and enzymatic activity.
- Extensive analytical comparability requirements.
- Limited patient numbers for clinical and post-approval development.
- Manufacturing scale and quality-system requirements.
A biosimilar competitor could face significant development expense despite the small commercial market. The cost-benefit calculation is more attractive for companies that already operate large-scale biologics facilities or have an established rare-disease franchise.
Patent risk is less clear than manufacturing risk because the value of individual patents depends on claim scope, prosecution history, terminal disclaimers, maintenance status and litigation outcomes. Later-expiring process or formulation patents could extend commercial protection beyond the expiration of core composition rights, but those patents would need to survive validity and infringement challenges.
What formulations and manufacturing methods are protected?
Vimizim is supplied as a sterile concentrate for intravenous infusion. The product must maintain biological activity and acceptable stability through manufacturing, storage, dilution and administration.
Relevant technical protection may cover:
- Recombinant expression in engineered host cells.
- Cell-culture conditions.
- Recovery and purification of the enzyme.
- Removal of host-cell proteins and process impurities.
- Control of aggregation and degradation.
- Glycan composition and enzyme activation.
- Sterile formulation and low-temperature storage.
- Release assays for potency, identity, purity and safety.
The manufacturing process is commercially important because enzyme replacement products are sensitive to structural variation. A biosimilar may meet the FDA’s similarity standard without being identical, but the sponsor must demonstrate that observed differences do not affect safety, purity or potency.[7]
Which companies compete with Vimizim?
Vimizim has no direct FDA-approved enzyme-replacement competitor for Morquio A syndrome. Its competitive environment consists of indirect therapies and products for adjacent lysosomal or mucopolysaccharidosis disorders.
| Product |
Sponsor |
Indication |
Relationship to Vimizim |
| Vimizim |
BioMarin |
MPS IV A |
Direct standard of care |
| Naglazyme |
BioMarin |
MPS VI |
Adjacent disease, not a substitute |
| Mepsevii |
Ultragenyx |
MPS VII |
Adjacent disease, not a substitute |
| Brineura |
BioMarin |
CLN2 disease |
Different disorder and mechanism |
| Supportive orthopedic and respiratory care |
Multiple providers |
Morquio A complications |
Used alongside Vimizim |
Gene therapy and substrate-reduction approaches could create longer-term competitive risk, but no approved alternative has displaced Vimizim in the core Morquio A treatment market through the cited period.
What licensing deals affect Vimizim?
Vimizim is primarily a BioMarin-developed and BioMarin-commercialized product. Public BioMarin filings do not identify a major third-party licensing arrangement that materially changes the product’s core economics in the United States.
International distribution and commercialization arrangements can affect geographic net revenue, but BioMarin retains the central economic interest in the product. The company’s ownership and specialty-commercial infrastructure reduce dependence on an external licensee.
What is the geographic coverage of Vimizim?
Vimizim has been commercialized in the United States and multiple international markets. Geographic performance depends on:
- National reimbursement decisions.
- Rare-disease diagnosis rates.
- Specialist access.
- Hospital infusion infrastructure.
- Local pricing and health-technology assessment.
- Import and cold-chain requirements.
The United States remains strategically important because of higher reimbursement levels and a relatively developed rare-disease treatment infrastructure. Europe and other markets provide patient access but generally impose greater price controls and budget scrutiny.
What generic or biosimilar launch risks exist?
The most credible entry scenario is a biosimilar, not a generic. A potential entrant would need to navigate:
- Reference-product exclusivity.
- BPCIA patent procedures.
- Patent litigation or negotiated settlement.
- FDA similarity and interchangeability requirements.
- Limited patient recruitment for any required clinical work.
- Complex commercial manufacturing.
- Payer substitution and physician confidence.
An initial biosimilar launch would likely produce less price erosion than a conventional generic launch. Specialty biologics often retain meaningful net pricing because treatment is physician-administered, patient populations are small and payers may require prior authorization rather than automatic substitution.
A realistic post-entry scenario is gradual share loss rather than an immediate collapse in Vimizim revenue. The magnitude would depend on whether one or multiple biosimilars enter, whether interchangeability is granted, and whether BioMarin uses contracting or patient-support programs to defend utilization.
What patent litigation and settlement risks affect Vimizim?
No material public Vimizim patent litigation or biosimilar settlement has been identified in the cited record. The absence of litigation means there is no confirmed court-imposed launch date or settlement-based entry date.
Future disputes could involve:
- Validity of composition claims.
- Infringement of process patents.
- Formulation and stability claims.
- Manufacturing-cell or purification claims.
- Method-of-treatment claims.
- BPCIA information-exchange procedures.
A settlement could permit an earlier biosimilar launch while preserving some BioMarin patent rights. Without a public settlement, the earliest commercial entry remains dependent on the timing of a biosimilar filing, FDA approval and patent resolution.
What is the financial outlook for Vimizim?
Vimizim should be viewed as a mature, cash-generating orphan biologic rather than a high-growth launch product. Its core financial profile has four characteristics:
- High revenue per treated patient.
- Low absolute patient volume.
- Durable demand once patients initiate therapy.
- Increasing long-term exposure to biosimilar and reimbursement pressure.
Revenue growth is likely to remain modest unless BioMarin expands diagnosis, increases treatment penetration in underdiagnosed markets or captures additional indications. The principal downside is a gradual decline after biosimilar entry, with net-price erosion and patient switching occurring over several years.
Vimizim’s financial importance to BioMarin is meaningful but diversified across the company’s broader rare-disease portfolio. The product’s mature revenue supports cash generation, while its concentration in one rare disease limits the risk of broad market disruption from conventional competition.
Key Takeaways
- Vimizim is BioMarin’s elosulfase alfa therapy for Morquio A syndrome, or MPS IV A.
- FDA approval occurred on February 28, 2014.
- U.S. orphan-drug exclusivity expired in February 2021.
- The 12-year U.S. biologic reference-product exclusivity period generally runs into 2026.
- Vimizim has no conventional generic pathway; future competition would come through biosimilar development.
- No FDA-approved Vimizim biosimilar or major public Vimizim patent settlement is identified in the cited record.
- Revenue reached a mature several-hundred-million-dollar annual range after launch.
- Manufacturing complexity, patient scarcity and analytical comparability create meaningful entry barriers.
- The principal long-term risks are biosimilar erosion, reimbursement pressure and treatment discontinuation.
- Vimizim remains commercially resilient because Morquio A patients have limited therapeutic alternatives.
FAQs
Is Vimizim a biologic or a small-molecule drug?
Vimizim is a recombinant biologic enzyme-replacement therapy. It is regulated under a BLA, not an NDA.
Can a generic version of Vimizim be approved?
No conventional generic can be approved through the ANDA pathway. A competitor would need to pursue the FDA’s biosimilar pathway for biologics.
Is Vimizim interchangeable with a future biosimilar?
Interchangeability would require a separate FDA determination. Approval as a biosimilar would not automatically establish pharmacy-level interchangeability.
Does Vimizim have patent protection beyond orphan exclusivity?
Potentially. Biologic protection can include composition, process, formulation, manufacturing and method-of-use patents, although the commercial effect depends on claim scope and enforceability.
What is the largest commercial threat to Vimizim?
The largest long-term threat is a high-quality biosimilar combined with payer pressure. In the near term, reimbursement constraints and treatment discontinuation are more immediate than direct product competition.
References
- U.S. Food and Drug Administration. (2014). Vimizim (elosulfase alfa) prescribing information.
- BioMarin Pharmaceutical Inc. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
- BioMarin Pharmaceutical Inc. (2023). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
- U.S. Food and Drug Administration. (2024). Orphan drug designation and exclusivity.
- U.S. Food and Drug Administration. (2024). Biosimilar and interchangeable biological product definitions.
- U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products.
- U.S. Food and Drug Administration. (2015). Scientific considerations in demonstrating biosimilarity to a reference product: Guidance for industry.
